Entrectinib
Other Protein Kinase Inhibitors
Sold as Rozlytrek
- Drug class
- Other Protein Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 5
Overview
Entrectinib is an active pharmaceutical ingredient in the Other Protein Kinase Inhibitors group (L01EX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 22, 2026 |
| EU European Union | EMA | 1 | June 10, 2025 |
| CA Canada | Health Canada | 2 | May 8, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
1). ROS1 gene fusion Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
How to take
EUEuropean Union· EMA
1 product
Uses
1). ROS1 gene fusion Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Entrectinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 449. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000310914 · revised May 22, 2026
- [2]European Medicines Agency · EMEA/H/C/004936 · revised June 10, 2025
- [3]Health Canada (DPD) · 02495007 · revised May 8, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.